Zhang Fujun, Wang Yiping
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School, Chinese Academy of Sciences, Shanghai 201203, China.
Mol Biotechnol. 2006 May;33(1):29-36. doi: 10.1385/MB:33:1:29.
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been shown to play a crucial role in atherosclerosis, and has been proposed as a promising target for drug discovery. Here, we cloned the Lp-PLA(2) gene from differentiated THP-1 cells, and inserted a carboxy-terminal His(6)-tagged version of the gene into the pPIC9 Pichia expression vector. The Lp-PLA(2) fusion protein was successfully expressed in Pichia pastoris expression system and could be rapidly purified to apparent homogeneity using a single-step purification method. The activity of our recombinant Lp-PLA(2) was strong when [3H] PAF was used as a substrate, and the Lp-PLA(2) inhibitor SB435495 exhibited an inhibitory curve against the recombinant Lp-PLA2 (IC50 = 15.93 +/- 1 microM). This novel recombinant Lp-PLA(2) could prove useful as a screening model for Lp-PLA(2) inhibitors, and may facilitate further investigation of this protein in atherosclerosis.
脂蛋白相关磷脂酶A2(Lp-PLA2)已被证明在动脉粥样硬化中起关键作用,并已被提议作为药物研发的一个有前景的靶点。在此,我们从分化的THP-1细胞中克隆了Lp-PLA2基因,并将该基因的一个羧基末端带有His(6)标签的版本插入到pPIC9毕赤酵母表达载体中。Lp-PLA2融合蛋白在毕赤酵母表达系统中成功表达,并且可以使用单步纯化方法快速纯化至表观均一性。当以[3H]PAF作为底物时,我们的重组Lp-PLA2活性很强,并且Lp-PLA2抑制剂SB435495对重组Lp-PLA2表现出抑制曲线(IC50 = 15.93 +/- 1 microM)。这种新型重组Lp-PLA2可能作为Lp-PLA2抑制剂的筛选模型有用,并可能促进对该蛋白在动脉粥样硬化中的进一步研究。